Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT06943521
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:50.998281+00:00
Published At
2025-12-11T00:00:00+00:00
Record Updated At
2025-12-11
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Head and Neck Squamous Cell Carcinoma (HNSCC)", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Cancer", "Gastric Cancer", "Biliary Tract Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)", "Breast Cancer", "Ovarian Cancer", "Cervical Cancer", "Endometrial Cancer", "Prostate Cancer", "Urothelial Carcinoma", "Neuroendocrine Tumor (NET)", "Neuroendocrine Carcinoma (NEC)", "Soft Tissue Sarcoma", "Nuclear Protein in Testis (NUT) Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-11"
protocolSection.identificationModule.nctId
"NCT06943521"
protocolSection.identificationModule.officialTitle
"A Phase I/II, Dose-escalation and Dose-optimization Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of MT-4561 in Patients With Various Advanced Solid Tumors and to Evaluate Effect of MT-4561 on Pharmacokinetics of Oral Midazolam"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Head and Neck Squamous Cell Carcinoma (HNSCC) (protocolSection.conditionsModule.conditions)
  • Non-small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
  • Esophageal Cancer (protocolSection.conditionsModule.conditions)
  • Gastric Cancer (protocolSection.conditionsModule.conditions)
  • Biliary Tract Cancer (protocolSection.conditionsModule.conditions)
  • Pancreatic Ductal Adenocarcinoma (PDAC) (protocolSection.conditionsModule.conditions)
  • Breast Cancer (protocolSection.conditionsModule.conditions)
  • Ovarian Cancer (protocolSection.conditionsModule.conditions)
  • Cervical Cancer (protocolSection.conditionsModule.conditions)
  • Endometrial Cancer (protocolSection.conditionsModule.conditions)
  • Prostate Cancer (protocolSection.conditionsModule.conditions)
  • Urothelial Carcinoma (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Tumor (NET) (protocolSection.conditionsModule.conditions)
  • Neuroendocrine Carcinoma (NEC) (protocolSection.conditionsModule.conditions)
  • Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Nuclear Protein in Testis (NUT) Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.